Beta Drugs Limited — Investor Meet, 15-05-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Beta Drugs has announced a board meeting to consider the financial results for the quarter and half-year. FY’25 revenue rose 23% YoY to ₹362 Cr, EBITDA grew 32% to ₹81 Cr, and PAT increased 26% to ₹45.8 Cr, with a strong EBITDA margin of 22.4%. Domestic oncology brands crossed ₹100 Cr, growing at a 5-year CAGR of 30%, while international business surged 73%. Management highlights growth via new product launches, expanded presence in 46+ countries, a strong R&D pipeline (25+ products), and focus on NDDS formulations and API manufacturing. Cash stands at ₹147 Cr, borrowings at ₹136 Cr, supporting expansion. Outlook remains confident on oncology, supportive care, and cosmeceuticals.